MNOV
MediciNova, Inc.
Biotechnology
Market Cap$70M
5Y Perf.-73.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MNOV vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
AVXL
Anavex Life Sciences Corp.
Biotechnology
Market Cap$289M
5Y Perf.-24.1%
MNOV vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNOV | AVXL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $70M | $289M |
| Revenue (TTM) | $410K | $0.00 |
| Net Income (TTM) | $-12M | $-40M |
| Gross Margin | 7.6% | — |
| Operating Margin | -32.4% | — |
| Total Debt | $194K | $0.00 |
| Cash & Equiv. | $31M | $103M |
MNOV vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNOV
AVXL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MediciNova, Inc. (MNOV) | 100 | 26.8 | -73.2% |
| Anavex Life Science… (AVXL) | 100 | 75.9 | -24.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNOV vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNOV leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Anavex Life Sciences Corp. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
MNOV
MediciNova, Inc.
The Income Pick
MNOV carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.31
- Lower volatility, beta 0.31, Low D/E 0.5%, current ratio 8.16x
- Beta 0.31, current ratio 8.16x
Best for: income & stability and sleep-well-at-night
AVXL
Anavex Life Sciences Corp.
The Growth Play
AVXL is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -3.8%
- -25.7% 10Y total return vs MNOV's -80.1%
- 4.5% margin vs MNOV's -29.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNOV | -8.8% revenue growth vs AVXL's -34.9% |
| Quality / Margins | AVXL | 4.5% margin vs MNOV's -29.3% |
| Stability / Safety | MNOV | Beta 0.31 vs AVXL's 1.51 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNOV | -4.0% vs AVXL's -63.2% |
| Efficiency (ROA) | MNOV | -26.3% ROA vs AVXL's -30.0% |
MNOV vs AVXL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNOVLAGGINGAVXL
AVXLAnavex Life Sciences …
1leads
MNOVMediciNova, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs AVXLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AVXL1/1
Valuation MetricsMultiples, price ratios, and targets
MNOV2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNOV4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MNOV5/6
Risk & VolatilityBeta, volatility, and downside exposure
MNOV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AVXL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MNOV and AVXL operate at a comparable scale, with $409,657 and $0 in trailing revenue.
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| RevenueTrailing 12 months | $409,657 | $0 |
| EBITDAEarnings before interest/tax | -$13M | -$30M |
| Net IncomeAfter-tax profit | -$12M | -$40M |
| Free Cash FlowCash after capex | -$10M | -$34M |
| Gross MarginGross profit ÷ Revenue | +7.6% | — |
| Operating MarginEBIT ÷ Revenue | -32.4% | — |
| Net MarginNet income ÷ Revenue | -29.3% | — |
| FCF MarginFCF ÷ Revenue | -23.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +4.7% | +54.4% |
AVXL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
MNOV leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| Market CapShares × price | $70M | $289M |
| Enterprise ValueMkt cap + debt − cash | $40M | $187M |
| Trailing P/EPrice ÷ TTM EPS | -5.96x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 171.21x | — |
| Price / BookPrice ÷ Book value/share | 1.69x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — |
MNOV leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
MNOV leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
MNOV delivers a -28.9% return on equity — every $100 of shareholder capital generates $-29 in annual profit, vs $-32 for AVXL. On the Piotroski fundamental quality scale (0–9), MNOV scores 3/9 vs AVXL's 2/9, reflecting mixed financial health.
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| ROE (TTM)Return on equity | -28.9% | -31.5% |
| ROA (TTM)Return on assets | -26.3% | -30.0% |
| ROICReturn on invested capital | -85.5% | — |
| ROCEReturn on capital employed | -28.0% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$31M | -$103M |
| Cash & Equiv.Liquid assets | $31M | $103M |
| Total DebtShort + long-term debt | $194,331 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
MNOV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MNOV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNOV five years ago would be worth $3,488 today (with dividends reinvested), compared to $2,759 for AVXL. Over the past 12 months, MNOV leads with a -4.0% total return vs AVXL's -63.2%. The 3-year compound annual growth rate (CAGR) favors MNOV at -13.2% vs AVXL's -28.1% — a key indicator of consistent wealth creation.
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| YTD ReturnYear-to-date | +7.5% | -15.2% |
| 1-Year ReturnPast 12 months | -4.0% | -63.2% |
| 3-Year ReturnCumulative with dividends | -34.7% | -62.9% |
| 5-Year ReturnCumulative with dividends | -65.1% | -72.4% |
| 10-Year ReturnCumulative with dividends | -80.1% | -25.7% |
| CAGR (3Y)Annualised 3-year return | -13.2% | -28.1% |
MNOV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
MNOV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNOV is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than AVXL's 1.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNOV currently trades 73.0% from its 52-week high vs AVXL's 22.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.31x | 1.51x |
| 52-Week HighHighest price in past year | $1.96 | $13.99 |
| 52-Week LowLowest price in past year | $1.17 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +73.0% | +22.3% |
| RSI (14)Momentum oscillator 0–100 | 55.8 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 47K | 1.4M |
MNOV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MNOVMediciNova, Inc. | AVXLAnavex Life Scien… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNOV leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). AVXL leads in 1 (Income & Cash Flow).
Best OverallMediciNova, Inc. (MNOV)Leads 4 of 6 categories
Loading custom metrics...
MNOV vs AVXL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MNOV or AVXL a better buy right now?
Analysts rate Anavex Life Sciences Corp.
(AVXL) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNOV or AVXL?
Over the past 5 years, MediciNova, Inc.
(MNOV) delivered a total return of -65. 1%, compared to -72. 4% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: AVXL returned -25. 7% versus MNOV's -80. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNOV or AVXL?
By beta (market sensitivity over 5 years), MediciNova, Inc.
(MNOV) is the lower-risk stock at 0. 31β versus Anavex Life Sciences Corp. 's 1. 51β — meaning AVXL is approximately 388% more volatile than MNOV relative to the S&P 500.
04Which is growing faster — MNOV or AVXL?
On earnings-per-share growth, the picture is similar: Anavex Life Sciences Corp.
grew EPS -3. 8% year-over-year, compared to -4. 3% for MediciNova, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNOV or AVXL?
Anavex Life Sciences Corp.
(AVXL) is the more profitable company, earning 0. 0% net margin versus -29. 3% for MediciNova, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVXL leads at 0. 0% versus -32. 4% for MNOV. At the gross margin level — before operating expenses — MNOV leads at 7. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNOV or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNOV or AVXL better for a retirement portfolio?
For long-horizon retirement investors, MediciNova, Inc.
(MNOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31)). Anavex Life Sciences Corp. (AVXL) carries a higher beta of 1. 51 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNOV: -80. 1%, AVXL: -25. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNOV and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.